BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Amin M, No DJ, Egeberg A, Wu JJ. Choosing First-Line Biologic Treatment for Moderate-to-Severe Psoriasis: What Does the Evidence Say? Am J Clin Dermatol 2018;19:1-13. [PMID: 29080066 DOI: 10.1007/s40257-017-0328-3] [Cited by in Crossref: 31] [Cited by in F6Publishing: 19] [Article Influence: 7.8] [Reference Citation Analysis]
Number Citing Articles
1 Membrive Jiménez C, Pérez Ramírez C, Sánchez Martín A, Vieira Maroun S, Arias Santiago SA, Ramírez Tortosa MDC, Jiménez Morales A. Influence of Genetic Polymorphisms on Response to Biologics in Moderate-to-Severe Psoriasis. J Pers Med 2021;11:293. [PMID: 33921427 DOI: 10.3390/jpm11040293] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
2 Gisondi P, Geat D, Pizzolato M, Girolomoni G. State of the art and pharmacological pipeline of biologics for chronic plaque psoriasis. Current Opinion in Pharmacology 2019;46:90-9. [DOI: 10.1016/j.coph.2019.05.007] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 6.3] [Reference Citation Analysis]
3 Shear NH, Betts KA, Soliman AM, Joshi A, Wang Y, Zhao J, Gisondi P, Sinvhal R, Armstrong AW. Comparative safety and benefit-risk profile of biologics and oral treatment for moderate-to-severe plaque psoriasis: A network meta-analysis of clinical trial data. J Am Acad Dermatol 2021;85:572-81. [PMID: 33631216 DOI: 10.1016/j.jaad.2021.02.057] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 Wu JJ, Lu M, Veverka KA, Smulders M, Papademetriou E, Yu J, Feldman SR. The journey for US psoriasis patients prescribed a topical: a retrospective database evaluation of patient progression to oral and/or biologic treatment. Journal of Dermatological Treatment 2019;30:446-53. [DOI: 10.1080/09546634.2018.1529386] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
5 Fowler E, Ghamrawi RI, Ghiam N, Liao W, Wu JJ. Risk of tuberculosis reactivation during interleukin-17 inhibitor therapy for psoriasis: a systematic review. J Eur Acad Dermatol Venereol 2020;34:1449-56. [PMID: 32012384 DOI: 10.1111/jdv.16254] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
6 Pirro F, Caldarola G, Chiricozzi A, Burlando M, Mariani M, Parodi A, Peris K, De Simone C. Impact of Body Mass Index on the Efficacy of Biological Therapies in Patients with Psoriasis: A Real-World Study. Clin Drug Investig 2021;41:917-25. [PMID: 34537921 DOI: 10.1007/s40261-021-01080-z] [Reference Citation Analysis]
7 Aschoff R, Bewley A, Dattola A, De Simone C, Lahfa M, Llamas-Velasco M, Martorell A, Pavlovic M, Sticherling M. Beyond-Mild Psoriasis: A Consensus Statement on Calcipotriol and Betamethasone Dipropionate Foam for the Topical Treatment of Adult Patients. Dermatol Ther (Heidelb) 2021;11:1791-804. [PMID: 34510404 DOI: 10.1007/s13555-021-00600-1] [Reference Citation Analysis]
8 Lebwohl M, Leonardi C, Armstrong A, Rawnsley N, Alexander B, Goehring E Jr, Kerdel F, Jacobson A. Three-year U.S. pharmacovigilance report of brodalumab. Dermatol Ther 2021;:e15105. [PMID: 34418244 DOI: 10.1111/dth.15105] [Reference Citation Analysis]
9 Kim HJ, Lebwohl MG. Biologics and Psoriasis: The Beat Goes On. Dermatol Clin 2019;37:29-36. [PMID: 30466686 DOI: 10.1016/j.det.2018.07.004] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
10 Wechter T, Cline A, Feldman SR. Targeting p19 as a treatment option for psoriasis: an evidence-based review of guselkumab. Ther Clin Risk Manag 2018;14:1489-97. [PMID: 30174431 DOI: 10.2147/TCRM.S177127] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
11 Kjærsgaard Andersen R, Saunte SK, Jemec GBE, Saunte DM. Psoriasis as a comorbidity of hidradenitis suppurativa. Int J Dermatol 2019;59:216-20. [DOI: 10.1111/ijd.14651] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
12 Enos CW, Ramos VL, McLean RR, Lin TC, Foster N, Dube B, Van Voorhees AS. Comorbid obesity and history of diabetes are independently associated with poorer treatment response to biologics at 6 months: A prospective analysis in Corrona Psoriasis Registry. J Am Acad Dermatol 2021:S0190-9622(21)02085-5. [PMID: 34256035 DOI: 10.1016/j.jaad.2021.06.883] [Reference Citation Analysis]
13 Wu JJ, Merola JF, Feldman SR, Menter A, Lebwohl M. Treatment of Psoriasis with Secukinumab in Challenging Patient Scenarios: A Review of the Available Evidence. Dermatol Ther (Heidelb) 2020;10:351-64. [PMID: 32242325 DOI: 10.1007/s13555-020-00373-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
14 Kolli SS, Gabros SD, Pona A, Cline A, Feldman SR. Tildrakizumab: A Review of Phase II and III Clinical Trials. Ann Pharmacother 2019;53:413-8. [PMID: 30345790 DOI: 10.1177/1060028018809522] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
15 Armstrong AW, Puig L, Joshi A, Skup M, Williams D, Li J, Betts KA, Augustin M. Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-analysis. JAMA Dermatol 2020;156:258-69. [PMID: 32022825 DOI: 10.1001/jamadermatol.2019.4029] [Cited by in Crossref: 43] [Cited by in F6Publishing: 34] [Article Influence: 21.5] [Reference Citation Analysis]
16 Raine T, Gkini MA, Irving PM, Kaul A, Korendowych E, Laws P, Foulkes AC. Maintaining Clinical Freedom Whilst Achieving Value in Biologics Prescribing: An Integrated Cross-Specialty Consensus of UK Dermatologists, Rheumatologists and Gastroenterologists. BioDrugs 2021;35:187-99. [PMID: 33635522 DOI: 10.1007/s40259-020-00464-5] [Reference Citation Analysis]
17 Prignano F, Choi J, Pieper B, Iversen L. Anti-tumor necrosis factor agents in psoriasis: addressing key challenges using biosimilars. Expert Opin Biol Ther 2021;21:75-80. [PMID: 32886008 DOI: 10.1080/14712598.2020.1812576] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
18 Barker J, Girolomoni G, Egeberg A, Goncalves J, Pieper B, Kang T. Anti-TNF biosimilars in psoriasis: from scientific evidence to real-world experience. J Dermatolog Treat 2020;31:794-800. [PMID: 31094242 DOI: 10.1080/09546634.2019.1610553] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
19 Drvar DL, Vlahinić T, Maleš Ž, Turčić P, Čeović R. A modern approach to the treatment of plaque psoriasis. Acta Pharm 2019;69:511-23. [PMID: 31639088 DOI: 10.2478/acph-2019-0047] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Campanati A, Paolinelli M, Diotallevi F, Martina E, Molinelli E, Offidani A. Pharmacodynamics OF TNF α inhibitors for the treatment of psoriasis. Expert Opin Drug Metab Toxicol 2019;15:913-25. [PMID: 31623470 DOI: 10.1080/17425255.2019.1681969] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
21 Özyurt K, Ertaş R, Atasoy M. Biologics for psoriasis: What is new? Dermatologic Therapy 2019;32. [DOI: 10.1111/dth.12916] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]